Rank #1542SAVA

Cassava Sciences, Inc.

$2.17

1.88% (Daily)

Market Cap

$104.83M

Revenue

$N/A

Rank by MCap

#1542

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Richard Jon Barry

Headquarters

Austin, TX

Employees

About Cassava Sciences, Inc.

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The compan...